THS et risque de cancer du sein - Résultats de la cohorte E3N

Translated title of the contribution: HRT and breast cancer risk - Results of the E3N-EPIC cohort

Agnès Fournier, Franco Berrino, Elio Riboli, Valérie Avenel, Françoise Clavel-Chapelon

Research output: Contribution to journalArticlepeer-review


Most epidemiological studies have shown an increase in breast cancer risk related to hormone replacement therapy (HRT) use. We assessed the risk of breast cancer associated with HRT use in 54,548 postmenopausal women who had never taken any HRT one year before entering the E3N-EPIC cohort study (mean age at inclusion: 52.8 years). 948 primary invasive breast cancers were diagnosed during follow-up (mean duration: 5.8 years). Data were analysed using multivariate Cox proportional hazards models. In this cohort where the mean duration of HRT use was 2.8 years, an increased risk in HRT users compared with non-users was found (relative risk (RR) 1.2 [95% confidence interval 1.1-1.4]). The RR was 1.1 [0.8-1.6] for estrogens used alone and 1.3 [1.1-1.5] when used in combination with oral progestogens. The risk was significantly greater (p

Translated title of the contributionHRT and breast cancer risk - Results of the E3N-EPIC cohort
Original languageFrench
Pages (from-to)186-193
Number of pages8
JournalReproduction Humaine et Hormones
Issue number5
Publication statusPublished - Jun 2005


  • Breast cancer
  • Cohort study
  • Hormone Replacement Therapy
  • Menopause
  • Risk factor

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'HRT and breast cancer risk - Results of the E3N-EPIC cohort'. Together they form a unique fingerprint.

Cite this